Short answer
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Exhibits 99.1 and 99.2 contain the substantive Regulation FD disclosure.
ANAVEX LIFE SCIENCES CORP. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibits 99.1 and 99.2 contain the substantive Regulation FD disclosure
- Exhibits excluded from Exchange Act Section 18 filing liability
- Exhibits not incorporated by reference into other SEC filings unless specifically referenced
Item EX-99.1 · Exhibit EX-99.1
- Proxy solicitation campaign urging stockholders to elect all six Anavex director nominees at the September 24, 2026 annual meeting
- Two new independent nominees add capital allocation, drug development, clinical research and global regulatory expertise
- Stockholders of record as of July 31, 2026 are eligible to vote using the WHITE proxy card
- VoteAnavex.com launched with nominee information, voting instructions and annual-meeting materials
- Board contest may influence Anavex’s go-forward strategy and oversight of its CNS drug-development programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANAVEX LIFE SCIENCES CORP. 8-K filings
Get the next AVXL 8-K as it lands
Follow AVXL for push alerts, or ask the research agent what this filing means.